Skip to main navigation Skip to search Skip to main content

Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Doubleblind, Active-Controlled Phase 3 Trial

  • Ui Yoon Choi
  • , Ki Hwan Kim
  • , Jin Lee
  • , Byung Wook Eun
  • , Hwang Min Kim
  • , Kyung Yil Lee
  • , Dong Ho Kim
  • , Sang Hyuk Ma
  • , Jina Lee
  • , Jong Hyun Kim
  • The Catholic University of Korea Incheon St. Mary's Hospital
  • Hanil General Hospital
  • Eulji University
  • Yonsei University Mirae Campus
  • Daejeon St. Mary's Hospital
  • Korea Institute of Radiological and Medical Sciences
  • Changwon Fatima Hospital
  • University of Ulsan

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Although the combination tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) is recommended at adolescence in developed countries, the tetanus and diphtheria toxoid vaccine (Td), which is less costly, is recommended instead in some parts of the world. A new Td, BR-TD-1001, was developed by a Korean manufacturer for distribution to endemic regions and for use in the initial step of novel Tdap development. Methods: This phase 3, randomized, double-blind, multi-center trial, conducted in Korea, aimed to evaluate the immunogenicity and safety of BR-TD-1001. Healthy children aged 10 to 12 years were randomized 1:1 to receive either BR-TD-1001 or the control Td (Td-pur, GlaxoSmithKline). Antibodies were measured using enzyme-linked immunosorbent assay. Results: A total of 218 subjects (BR-TD-1001, n = 108; control, n = 110) was enrolled and included in the safety analysis. Vaccine-mediated antibody responses were similar in both groups. We confirmed the non-inferiority of BR-TD-1001 against the control, Td; 100% of both groups achieved seroprotection against diphtheria and tetanus. Furthermore, there was no significant difference between groups in the proportion of participants who demonstrated boost responses against diphtheria and tetanus toxoids. The incidence of solicited local and systemic adverse events (AEs), unsolicited AEs, and serious AEs did not differ significantly between groups. Conclusion: The BR-TD-1001 satisfied the immunological non-inferiority criterion against diphtheria and tetanus, with a clinically acceptable safety profile.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalJournal of Korean Medical Science
Volume36
Issue number49
DOIs
StatePublished - 2021

Bibliographical note

Publisher Copyright:
© 2021 The Korean Academy of Medical Sciences. All Rights Reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical Trial
  • Diphtheria Toxoid
  • Immunity
  • Safety
  • Tetanus Toxoid

Fingerprint

Dive into the research topics of 'Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Doubleblind, Active-Controlled Phase 3 Trial'. Together they form a unique fingerprint.

Cite this